Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.

Medicine & Life Sciences

• Tenofovir 100%
• Mutation Rate 83%
• HIV-1 68%
• Reverse Transcriptase Inhibitors 56%
• Nucleotides 31%
• Population 30%
• Therapeutics 12%
• Emtricitabine 11%
• Mutation 8%
• Nucleosides 8%
• Protease Inhibitors 8%
• Guidelines 5%

Agriculture & Biology

• Human immunodeficiency virus 1 96%
• RNA-directed DNA polymerase 93%
• therapeutics 61%
• mutation 53%
• nucleotides 46%
• nucleosides 14%
• proteinase inhibitors 13%

Earth & Environmental Sciences

• human immunodeficiency virus 98%
• therapy 83%
• mutation 78%
• inhibitor 73%
• rate 25%
• trend 5%